<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7C2C94DE-03A4-41D6-9FE7-7A0D8893D3D2"><gtr:id>7C2C94DE-03A4-41D6-9FE7-7A0D8893D3D2</gtr:id><gtr:name>CellCentric Ltd</gtr:name><gtr:address><gtr:line1>Chesterford Research Park</gtr:line1><gtr:postCode>CB10 1XL</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3B20713-956F-4D17-9AF7-B561CCBAE326"><gtr:id>E3B20713-956F-4D17-9AF7-B561CCBAE326</gtr:id><gtr:name>University of Bologna</gtr:name><gtr:address><gtr:line1>Via Irnerio 46</gtr:line1><gtr:postCode>40126</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Cambridge Institute for Medical Research</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7C2C94DE-03A4-41D6-9FE7-7A0D8893D3D2"><gtr:id>7C2C94DE-03A4-41D6-9FE7-7A0D8893D3D2</gtr:id><gtr:name>CellCentric Ltd</gtr:name><gtr:address><gtr:line1>Chesterford Research Park</gtr:line1><gtr:postCode>CB10 1XL</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3B20713-956F-4D17-9AF7-B561CCBAE326"><gtr:id>E3B20713-956F-4D17-9AF7-B561CCBAE326</gtr:id><gtr:name>University of Bologna</gtr:name><gtr:address><gtr:line1>Via Irnerio 46</gtr:line1><gtr:postCode>40126</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/748DF1D8-D39E-4047-B5CC-0D6864CA4C1A"><gtr:id>748DF1D8-D39E-4047-B5CC-0D6864CA4C1A</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Huntly</gtr:surname><gtr:orcidId>0000-0003-0312-161X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FM010392%2F1"><gtr:id>B910F0A1-55C0-43EA-9F1A-4A821E11A3D9</gtr:id><gtr:title>Characterising and targeting aberrant enhancer function in acute myeloid leukaemia (AML)</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/M010392/1</gtr:grantReference><gtr:abstractText>Acute myeloid leukaemia (AML) is an aggressive haematological cancer. It is the most common acute leukaemia in Europe, with an incidence of 3-4 per 100,000 of the population. In addition, its incidence rises with age, therefore it will become an increasingly common problem as the general population ages. AML has a dismal overall survival rate of less than 30% and the mainstay of treatment aggressive, toxic, combination chemotherapy has remained ostensibly unchanged for the last 25 years. Novel therapies are therefore urgently required to improve treatment outcomes in AML. Where a greater knowledge of the mechanisms of disease have been uncovered, therapeutic gains have often been achieved. The most impressive example of this is the acute promyelocytic leukaemia subtype, where an understanding of the mechanisms that underlie this subtype has led to the development of novel therapies (All Trans Retionoic Acid, ATRA and arsenic trioxide) that can cure up to 90% of patients. Therefore, a better understanding of AML biology is a pre-requisite for the development of novel therapies to improve treatment outcomes.

Recently, a number of studies have documented that AML is associated with abnormal expression of genes and we and others have shown that correction of these abnormal gene programmes, with drugs such as small molecule inhibitors, may be a promising therapy. The expression of genes varies greatly between different tissues in the body and these differences are regulated by DNA elements called enhancers. Enhancers regulate the expression of genes by communication with promoters (the DNA start sites of genes) in a tissue-specific manner, such that for a gene X, there may be a number of different enhancers that regulate the expression of X in different tissues such as blood, brain and skin. Enhancers are a often a long distance away from promoters and require 3-dimensional contact with promoters through the formation of DNA loops. The function of enhancers is in turn controlled and modelled by molecules called transcription factors and regulators of chromatin (DNA and its protein scaffold). Recent work has shown that enhancers, transcription factors (TF) and chromatin regulators are all recurrently and commonly mutated in AML. We therefore propose that abnormal enhancer function is causative in AML and that it may be possible to therapeutically target this abnormal function to correct abnormal gene expression programmes thereby switching off leukaemia.

This proposal will address how enhancer usage and function differ during the evolution of AML from normal haematopoiesis, the process of normal blood formation. To allow us to model this prospectively, we will use mouse models with different combinations of AML-specific mutations that mimic different stages of the disease: normal, pre-leukaemic and frankly leukaemia stages. We will compare the presence, usage and function of enhancers between stages using the binding of specific proteins to DNA, a technique called ChIP-Seq. In addition, using another cutting-edge technique called Hi-C, we will map looping interactions between enhancers and promoters and how these differ by stage of disease. We will also measure the end output, that is expression of genes, detailing differences between the stages and how these correlate with enhancer usage. We will then compare these patterns to human leukaemia's that carry the same mutations. These data will allow us to identify the TF and chromatin regulators that control leukaemia specific enhancers. Our last objective will be to inhibit these factors, as a proof of concept that enhancer function may be a therapeutic target. We will use drug-like small molecular inhibitors and genetic techniques to alter the function of these regulators and will look for alterations of leukaemia growth and gene expression both in test tube experiments and live models of leukaemia.</gtr:abstractText><gtr:technicalSummary>Acute Myeloid Leukaemia (AML) is an aggressive and often incurable haematological malignancy. Gene expression and mutational studies highlight the importance of abnormal transcription in the induction and maintenance of the leukaemia phenotype. Recent studies of normal transcription have documented the importance of specific enhancers, cis-regulatory elements often at long distances from the genes they regulate, in the induction and maintenance of tissue specific gene expression patterns. Growing evidence links aberrant enhancer function with malignancies such as AML and we propose to document alterations in the enhancer landscape that accompany the evolution of AML.

We will use an allelic series of sophisticated mouse strains that model the development of AML at the cellular level. Using pertinent haematopoietic stem and progenitor cell populations from each of these models, we will document alterations in gene expression, enhancer usage and function and enhancer-promoter interactions using state-of-the-art global genomics techniques such as RNA-Seq, ChIP-Seq and Capture Hi-C (CHI-C). We will then correlate the changes in our murine models with the enhancer landscape of human AML with a similar genotype. Finally, we will aim to identify transcription factors and chromatin rmodifiers that are critical for AML enhancer function and will test the therapeutic potential of perturbing these critical regulators with experimental and pharmacological intervention.</gtr:technicalSummary><gtr:potentialImpactText>Although Acute Myeloid Leukaemia (AML) is a relatively rare disease, it is highly aggressive. Of the 2200 or so patients diagnosed each year in the UK, around 1800 will not survive long-term. AML is therefore an unmet medical need. In addition to this social burden to the UK and beyond, it places a significant financial burden on the NHS. Curative treatment is highly intensive, which is arduous for the patient, expensive (over &amp;pound;60K/patient) and requires prolonged hospital admissions, representing a significant cost to the NHS. Allogeneic stem cell transplantation (alloSCT) provides a powerful approach to reduce relapse, but again is costly (&amp;pound;50-100K/ transplant) and is associated with significant toxicity (an upfront mortality rate of between 10-30%). The mainstay of treatment, standard combination chemotherapy, appears to have reached the ceiling of its impact, therefore, there is an urgent need for novel therapeutics in AML. However, where the biology of the disease is well characterized, such as in the acute promyelocytic leukaemia (APML) subtype, improvements have been dramatic, with cure rates now exceeding 90% for this subtype. Theses data prioritise a better understanding of AML biology as a pre-requisite for the development of novel therapies to improve treatment outcomes.

Recently, it has been demonstrated that the generation of tissue specific patterns of gene expression, which occurs during development and differentiation, involves the interplay of combinatorial patterns of specific enhancer elements with their cognate promoters. We predict that the normal remodelling of enhancers, required to generate specialised transcriptional programmes necessary for haematopoietic differentiation and development, is corrupted during the evolution of leukaemia, giving rise to aberrant transcription which maintains the tumour. In the majority of AML cases, although we know that transcription is altered to drive the leukaemic phenotype, the mechanisms that initiate a maintain these aberrant transcriptional programmes are poorly understood. Details of transcriptional alterations during leukaemia evolution, the mechanisms involved and how these might be therapeutically targeted, would not only inform leukaemogenesis and the normal transcriptional regulation of haematopoiesis, but may also identify novel therapeutic targets and therapies themselves.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-03-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-30</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>526177</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>Using chromosome conformation capture analysis to study fumarate</gtr:description><gtr:id>4105BA9B-BDD9-491C-BC18-6C87D1458125</gtr:id><gtr:impact>The study has been published (Sciacovelli et al. Nature 2016) showing loss of fumarate hydratase and fumarate accumulation contribute to the aggressive features of fumarate hydratase-deficient tumours with important implications for their future treatment.</gtr:impact><gtr:outcomeId>58b6892b93aaf8.95333464-1</gtr:outcomeId><gtr:partnerContribution>Wider study of the role of fumarate in the development of renal cancer</gtr:partnerContribution><gtr:piContribution>Performing chromosome conformation capture experiments</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bologna</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Study of the leukemogenetic potential of novel and rare gene fusions</gtr:description><gtr:id>BF296DB9-0BC6-43F1-84D8-B103215BF962</gtr:id><gtr:impact>The study should improve our understanding of novel and rare gene fusions and explore their potential as innovative targets for personalized therapies approaches within Acute Myeloid Leukaemia.</gtr:impact><gtr:outcomeId>58bff7fd0f2955.18411151-1</gtr:outcomeId><gtr:partnerContribution>Production of gene fusions e.g. ZEB2-BCL11B</gtr:partnerContribution><gtr:piContribution>Expertise in mouse modelling and advice with experimental design.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Regenerative Medicine</gtr:department><gtr:description>Study of MLL-AF4+ infant B cell acute lymphoblastic leukaemia</gtr:description><gtr:id>8F431A4F-B9FF-419E-B227-8E82C171B707</gtr:id><gtr:impact>Study published as Barrett et al. Cell Rep 2016 increases our knowledge of a previously poorly understood childhood cancer and identifies of how future study could increase this further still.</gtr:impact><gtr:outcomeId>58b6ed9e647848.15711559-1</gtr:outcomeId><gtr:partnerContribution>The majority of experiments and overall direction of the study.</gtr:partnerContribution><gtr:piContribution>Assistance with experiments, particularly assays and mouse modelling, and also data analysis.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CellCentric Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Application of CREBBP/p300 inhibitor programme to haematological malignancies</gtr:description><gtr:id>E350711C-17DC-42EB-8BD7-81EBF62538FE</gtr:id><gtr:impact>It is too early for any concrete outputs.</gtr:impact><gtr:outcomeId>58b5c2e6ea36e8.13223039-1</gtr:outcomeId><gtr:partnerContribution>Making available a CREBBP/p300 inhibitor which they have developed</gtr:partnerContribution><gtr:piContribution>Expertise in researching the biology of CREBBP/Crebbp as it relates to HSC function and its subversion in haematological malignancies. Relevant cell lines and mouse models.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cambridge Science festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A855DA59-B1F4-43CE-99C7-4CE26C8329BA</gtr:id><gtr:impact>Structured talk and open discussion thereafter

Sparked lab visits and a video re blood cancers which will be filmed by our stem cell institute.</gtr:impact><gtr:outcomeId>5644c4d9f37e56.65296364</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ERC Consolidator award</gtr:description><gtr:end>2020-08-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:fundingRef> 647685</gtr:fundingRef><gtr:id>1006E515-148C-48AD-820A-C6E7EA25607D</gtr:id><gtr:outcomeId>56dff9741d4b47.95696184</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI Chronic Myeloid Leukaemia (CML) working party</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>381C7FA5-AE72-44DD-8319-E753A2272586</gtr:id><gtr:impact>To define and implement treatment policy for the UK clinical community in CML. To decide upon the nature of national trials in this disease</gtr:impact><gtr:outcomeId>Av4DwFq7j3R</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI AML working group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E71F801E-F6EF-4813-A579-356C6EA6576E</gtr:id><gtr:outcomeId>fEPrRtevqgX</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Academic representative on national JRCPTB Haematology specialist advisory committee (SAC)</gtr:description><gtr:geographicReach>Local/Municipal/Regional - UK Only</gtr:geographicReach><gtr:id>A3FB257E-6298-416F-A747-24DFBEAFDB65</gtr:id><gtr:outcomeId>T5LhbwTtnEx</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>This is a novel mouse model that allows identification of mechanisms of blast crisis progression, using transposon-based insertional mutagenesis on the background of chronic phase Chronic Myeloid Lymphoma as published in Giotopoulos et al. J Exp Med 2015.</gtr:description><gtr:id>D72BAE53-3511-43FC-A115-361974EF01FE</gtr:id><gtr:impact>The model greatly informs the biology of Chronic Myeloid Lymphoma progression and provides a potent resource for the development of candidate therapies to improve the dismal outcomes in this highly aggressive disease.</gtr:impact><gtr:outcomeId>58c0425fedc362.03777153</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Blast crisis progression model</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>888A359C-07BE-4EEF-A76A-234A5A373D7D</gtr:id><gtr:title>A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c915abf12f4eea3ffb43e8cc979e3dd9"><gtr:id>c915abf12f4eea3ffb43e8cc979e3dd9</gtr:id><gtr:otherNames>Tzelepis K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b5bf78964487.63330011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>485A4538-91EB-46D7-AD88-418790B596D9</gtr:id><gtr:title>Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8135522522d0f4f3afd47e38c2cd073"><gtr:id>f8135522522d0f4f3afd47e38c2cd073</gtr:id><gtr:otherNames>Barrett NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b5bf77bc1928.82683243</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06BE0ABF-8B35-43A0-9813-F3A3CE8C8D29</gtr:id><gtr:title>Independence of epigenetic and genetic diversity in AML.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8b40d022ffda09dcdb0316114d8ee89"><gtr:id>f8b40d022ffda09dcdb0316114d8ee89</gtr:id><gtr:otherNames>Sasca D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>58b5bf77935e35.94758999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C512938-6D00-4A54-B7FC-91CA0011BA4D</gtr:id><gtr:title>Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa63804623afefe42d3849f6aead48b0"><gtr:id>fa63804623afefe42d3849f6aead48b0</gtr:id><gtr:otherNames>Grimwade D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>56dff872130d67.02291784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBC0CC97-ED66-424F-BAA0-8A7D15A51C60</gtr:id><gtr:title>A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5eba0717f938f8bd1d12a298fa310f0e"><gtr:id>5eba0717f938f8bd1d12a298fa310f0e</gtr:id><gtr:otherNames>Kollmann K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>58b5bf784aa257.41769403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>142A88BC-0DE9-432C-B767-9729480FC9AD</gtr:id><gtr:title>Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9dcac9014b753b41b120fcd89c559d2"><gtr:id>e9dcac9014b753b41b120fcd89c559d2</gtr:id><gtr:otherNames>Horton SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>5a9bea8fac0821.78635734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79F183EF-A08B-42AB-88A0-0489A22C5BE7</gtr:id><gtr:title>Glutaminolysis is a metabolic dependency in FLT3acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035c63ff96225395bd2b56789780be9a"><gtr:id>035c63ff96225395bd2b56789780be9a</gtr:id><gtr:otherNames>Gallipoli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a9bea901d5299.41817257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBDF85BA-26EA-4ABA-9129-8E5A3C658B78</gtr:id><gtr:title>Novel epigenetic therapies in hematological malignancies: Current status and beyond.</gtr:title><gtr:parentPublicationTitle>Seminars in cancer biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035c63ff96225395bd2b56789780be9a"><gtr:id>035c63ff96225395bd2b56789780be9a</gtr:id><gtr:otherNames>Gallipoli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1044-579X</gtr:issn><gtr:outcomeId>5a9bea8f797bd5.63927575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5FCD201-ADEC-49BB-9BA9-D7DBA294B165</gtr:id><gtr:title>Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac49b0457a941477ada423553ad6694"><gtr:id>3ac49b0457a941477ada423553ad6694</gtr:id><gtr:otherNames>Booth CAG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>5a9bea8fe37637.86495308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45D23872-E563-461F-8B47-B7D688789E8F</gtr:id><gtr:title>A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25e7ef96c987bab57366486500d42222"><gtr:id>25e7ef96c987bab57366486500d42222</gtr:id><gtr:otherNames>Giotopoulos G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>5644bfe2e66418.68653957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD48BF00-CDB8-4C22-BA08-93F9D726AEE4</gtr:id><gtr:title>Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf39094ef632ebbb42066741ffd829ea"><gtr:id>cf39094ef632ebbb42066741ffd829ea</gtr:id><gtr:otherNames>Sciacovelli M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>58b5bf77ec58e0.82771345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6548E702-B9DF-43CF-B66B-F37267E69128</gtr:id><gtr:title>Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46876f4e7c662ddb25c33f54fe22f57d"><gtr:id>46876f4e7c662ddb25c33f54fe22f57d</gtr:id><gtr:otherNames>McKerrell T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>58b5bf7730c189.36270482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AC42317-848D-4ABB-BBB5-5A250E417E39</gtr:id><gtr:title>Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia.</gtr:title><gtr:parentPublicationTitle>BMC cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf9a4b415a8696967a5bf0e850388395"><gtr:id>bf9a4b415a8696967a5bf0e850388395</gtr:id><gtr:otherNames>van der Weyden L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2407</gtr:issn><gtr:outcomeId>5644bfe2c53b26.73638560</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6FAC6CC-9E48-4B61-B80A-DB4374526214</gtr:id><gtr:title>Functional interdependence of BRD4 and DOT1L in MLL leukemia.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bec1f9b29647aec06d16e46865285977"><gtr:id>bec1f9b29647aec06d16e46865285977</gtr:id><gtr:otherNames>Gilan O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>58b5bf77691a18.47811807</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5D549AA-1D00-4C4E-9696-A7D3ADFA705D</gtr:id><gtr:title>Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Therapeutic advances in hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035c63ff96225395bd2b56789780be9a"><gtr:id>035c63ff96225395bd2b56789780be9a</gtr:id><gtr:otherNames>Gallipoli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2040-6207</gtr:issn><gtr:outcomeId>5644bfe2849845.58851741</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3A099E4-C575-4E04-BF19-7EDF355E13A5</gtr:id><gtr:title>The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25e7ef96c987bab57366486500d42222"><gtr:id>25e7ef96c987bab57366486500d42222</gtr:id><gtr:otherNames>Giotopoulos G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>5644bfe25d5366.74202513</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F08F14C-8BE5-448C-851D-4B84DE25B7F5</gtr:id><gtr:title>BET inhibitor resistance emerges from leukaemia stem cells.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad976a4ea7adb3c958c7fdef4bb46fb1"><gtr:id>ad976a4ea7adb3c958c7fdef4bb46fb1</gtr:id><gtr:otherNames>Fong CY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5644bfe314c293.04460839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96FCE12D-193E-4E53-82BF-661CADA37CF3</gtr:id><gtr:title>Actin dynamics tune the integrated stress response by regulating eukaryotic initiation factor 2a dephosphorylation.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d57a0e36b803efa1b2770dd37b5af573"><gtr:id>d57a0e36b803efa1b2770dd37b5af573</gtr:id><gtr:otherNames>Chambers JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>585d506b940120.81789090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89EADC91-CA42-492C-A84D-F46ACA797489</gtr:id><gtr:title>BET bromodomain inhibitors in leukemia.</gtr:title><gtr:parentPublicationTitle>Experimental hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6df0ea77406d4e814f76fc7890c2b016"><gtr:id>6df0ea77406d4e814f76fc7890c2b016</gtr:id><gtr:otherNames>Basheer F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0301-472X</gtr:issn><gtr:outcomeId>5644bfe2a571e0.37805133</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M010392/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>